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Abstract
Background: To compare tumor necrosis in hepatoma induced in rats by a single percutaneous
injection of ethanol (PEI) or acetic acid (PAI).
Methods: BW7756 hepatomas of 1 mm3 were implanted in the liver of 40 male healthy rats. After
14 days, the 36 surviving rats were treated, in a single session, by ultrasound-guided injection of
300 μl of 95% ethanol (n = 17) or 100 μl of 50% acetic acid (n = 19). They were sacrificed 14 days
after treatment and explanted tumoral livers were examined. The same PAI procedure was
repeated on 13 additional rats to exclude a suspected occurrence of technical failures during the
experiment, due to a surprisingly high rate of deaths within 30 minutes after PAI.
Results: Four rats died within four days after tumor implantation; after PEI, 1/17 (6%) died,
whereas after PAI 9/19 (47%) died. The remaining 26 rats, after 14 days post-percutaneous ablation,
were sacrificed. Gross and microscopic examinations showed that the hepatoma's nodules treated
with PEI had 45.3 ± 19.4% tumor necrosis compared to 49 ± 23.3% (P = NS) for those treated with
PAI. Complete tumor necrosis was not found in any animal. Peritoneal invasion was present in 4/
16 (25%) and 2/10 (20%) rats treated with PEI or PAI, respectively (P = NS). Autopsy was
performed in the 5 additional rats that died within 30 minutes after PAI.
Conclusion: Our results show that there is no significant difference in the percentage of tumor
necrosis between two local ablation methods in spite of the different dosages used. However,
mortality in the PAI-treated group was greater than in PEI-treated group, presumably due to
greater acetic acid systemic diffusion and its metabolic side effects. In human subjects, HCC occurs
in the setting of cirrhosis, where the non-tumoral tissue is firmer than the tumor structure, with
consequent reduction of drug diffusion. This could be the reason why some human studies have
concluded similar or even better safety and efficacy with PAI compared to PEI.
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Background
Several methods of percutaneous ablation of hepatocellu-
lar carcinoma (HCC) have been developed worldwide,
but which of these approaches is the most effective against
this liver tumor is still an issue of debate [1,2].
Percutaneous acetic acid injection (PAI) has been reported
to have a stronger cytotoxic effect and a lower rate of local
recurrence than percutaneous ethanol injection (PEI) in
the treatment of small HCCs [3,4]. The same authors
underline that the necrosis capacity of PAI is equivalent to
that of PEI at an acetic acid concentration of 15% whereas
a greater killing effect is reached at a 50%. Other authors
have also shown that PAI is effective in the treatment of
small HCCs in a single high-dose session [5].
In humans, PEI is known to be the best and most com-
mon treatment for HCCs smaller than 3 cm when there
are no more than three tumoral lesions, resulting in
induction of necrosis as a result of cellular dehydration,
protein denaturation, and chemical occlusion of tumor
vessels [6]. However, some authors believe that PEI neces-
sitates more treatment sessions than PAI and has a higher
rate of local recurrence [4].
The aim of this study was to evaluate safety and efficacy of
a single ultrasound-guided session of PEI in comparison
to a single session of PAI in male rats with BW7756
hepatoma [7-9].
Methods
Approval for this protocol was obtained from the Ethical
Committee of the Catholic University of Rome.
Animals
Fifty-three male healthy rats (weight 250–260 g, age 14
weeks), housed in autoclaved cages under barrier-sus-
tained conditions with controlled temperature (27°C)
and humidity (30%), were used.
All animal studies were performed in accordance with the
regulations of the National Institute of Health.
Tumor implantation
BW7756 murine hepatoma, an extensively studied tumor
that undergoes an exponential growth spurt in the 14–21
days post-implantation, was obtained from the Institute
of General Pathology (Catholic University of Rome).
Before starting the implantation procedure, anaesthesia
was induced in all rats by an intramuscular injection of a
mixture of 2 ml of Ketamine and 1 ml of Medetomidine.
Open laparotomy was performed through midline xifo-
pubic incision to expose the liver by means of mosquito
forceps and 1 mm3 of BW7756 hepatoma was directly
inserted into the liver of all rats following a modified Yang
technique [10]. Intrahepatic tumor implantation was car-
ried out after a small incision was done in the liver for the
purpose of both hemostasis and formation of a tension-
free pocket to accept the hepatoma; to this site the tumor
was secured with resorbable microsuture. After the
implantation, the liver with the fastened tumor was
reintroduced into the abdominal cavity and the abdomen
was closed using resorbable sutures. Post-operatively, the
animals were evaluated daily for diarrhea, loss of hair,
food intake and unusual behaviour.
PEI and PAI procedures
After 14 days post-hepatoma implantation, the liver of all
rats was sonographically revaluated to check the tumor
volume and percutaneous ultrasound-guided ablation
was performed immediately, using General Electric 400
equipment and a convex 10 MHz probe. Rats were rand-
omized before starting the procedure and then were anes-
thetized anew as previously described. They were placed
in the supine position, the abdominal area was accurately
shaved and disinfected, and all 36 rats were treated, in a
single session: 17 with percutaneous (300 µl 95%) etha-
nol injection (PEI) and 19 with (100 µl 50%) acetic acid
injection (PAI). The different dosage was decided consid-
ering different tissue distribution and greater diffusion of
acetic acid compared to ethanol [11].
In addition, to exclude that technical failures were the
cause of the observed high number of deaths among the
PAI treated rats, we repeated the experiment with the same
modalities treating another consecutive number of rats
(13 rats) with acetic acid injection (100 µl 50%).
Pathologic examination
After 14 days from percutaneous injection, all rats (age of
18 weeks) were sacrificed by cervical dislocation and the
liver was explanted en bloc and fixed in 10% buffered for-
maldehyde. At the end of the second experiment with PAI,
autopsy was performed on the five rats that died within 30
minutes after the procedure.
After gross observation of the liver and the abdominal cav-
ity, tissue samples were embedded in paraffin and then
processed conventionally.
Five micron tissue sections were stained with hematoxy-
lin-eosin (H&E) for microscopic examination at magnifi-
cations between 10× and 40× using Nikon ECLIPSE
E1000M microscopy.
The necrosis percentage is expressed as the mean ratio
between the necrotic area and the total tumor area (×100)
of ten fields, observed through panoramic lens.BMC Gastroenterology 2007, 7:45 http://www.biomedcentral.com/1471-230X/7/45
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Statistical analysis
All data are expressed as the mean ± SD. Data were ana-
lysed using the Prism statistical package (Graphpad Instat,
version 3). Throughout this study, Fisher's exact test and
Mann-Whitney's test for two-tail nonparametric variables
were used to determine if there were differences in the
studied groups. The results with a P-value < 0.05 were con-
sidered significant.
Results
Within one week after BW7756 hepatoma implantation,
4/40 rats (10%) died from post-surgical complications
and tumor growth that locally invaded the surrounding
organs, causing ascites and metastases to the lung.
The 36 surviving rats were randomly divided into two
groups: 17/36 (47.2%) for PEI and 19/36 (52.8%) for PAI
ablation. Before percutaneous injection, the hepatomas
mean volumes were: 1217 ± 300 mm3 and 1320 ± 100
mm3 in the PEI and PAI treatment groups, respectively
(P=NS), and no extrahepatic infiltration was detected.
Subsequently, all rats underwent ultrasound-guided per-
cutaneous injection of the neoplastic nodules.
Among PEI treated rats, one out of 17 (6%) died three
days after the procedure, while in the PAI group 9/19 rats
(47%) died within one week after the procedure (P <
0.01) (Figure 1). Pathologic examination disclosed a peri-
toneal and vessel neoplastic infiltration as the cause of
death in the PEI-treated rat and in four out of nine PAI-
treated rats (P=NS). Autopsy was not performed in the
other five PAI-treated rats died within 30 minutes after the
procedure.
After 14 days post-percutaneous ablation, all surviving
rats were sacrificed: gross and microscopic examinations
showed that peritoneal invasion was present in 4/16
(25%) and 2/10 (20%) rats receiving PEI and PAI treat-
ment, respectively (P = NS), whereas in no lesion was
complete necrosis found.
The calculated percentage of necrosis produced with the
injection of 300 µl of 95% ethanol was 45.3 ± 19.4%,
whereas with the injection of 100 µl of 50% acetic acid
was 49 ± 23.3% (P = NS) (Figure 2). There were no differ-
ences evident in the necrosis determined by acetic acid or
ethanol. Histological changes after injection of either
agent determined areas of reduced cell number with
degeneration of cytoplasmic and nuclear components and
cellular debris (Figure 3), intermingled with viable neo-
plastic cells localized in perivascular and central areas of
the hepatoma (Figure 4).
In this first experiment we observed a higher number of
deaths in the PAI treated rat group compared to the PEI
treated rat group, which seemed somewhat surprising to
us. Therefore, we repeated the PAI procedure treating a
consecutive number of 13 rats with 100 µl of 50% acetic
acid injection to exclude technical failures; we obtained
the same number of dead rats (n. 5) within 30 minutes
after the procedure as observed in the previous experi-
ment. Autopsy was promptly carried out on these 5 rats
(5/13 – 38.5%) and pathologic examination showed that
the cause of death was a massive (about 40%) liver necro-
sis with diaphragma involvement observed in three rats or
a complete inferior vena cava thrombosis with extension
Comparison of necrosis percentage induced by percutaneous  acetic acid injection (PAI) and percutaneous ethanol injection  (PEI) Figure 2
Comparison of necrosis percentage induced by percutaneous 





















Comparison of overall survival between rats with hepatoma,  treated with percutaneous ethanol injection (PEI) and percu- taneous acetic acid injection (PAI), before being sacrificed Figure 1
Comparison of overall survival between rats with hepatoma, 
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to right atrium (probably as a result of the activation of
blood coagulation factors) seen in the remaining two rats.
The calculated percentage of necrosis produced by the
injection of acetic acid in the eight surviving rats of this
new experiment was 54 ± 28.3% (the difference with that
of the previously studied rats is not statistically signifi-
cant).
Discussion
Acetic acid injection and ethanol injection are considered
to be a rational alternative to surgical resection and, in
particular, PEI seems to be the safest and most effective
percutaneous treatment for resectable and unresectable
HCCs <3 cm in humans [6,12-14]. Several studies have
emphasized the suitability of both PEI and PAI for multi-
ple session treatment of human HCCs [3,6,13-16].
Single high doses of PEI and PAI have also been investi-
gated to evaluate safety and efficacy in human HCCs with
good quality results [5,14,17].
An interesting study performed in patients with HCC on
the waiting list for liver transplantation showed that most
patients with solitary nodules <4 cm who received PEI had
90% to 100% tumor necrosis [18].
However, some studies have compared the effectiveness
of PEI and PAI in HCCs of humans or in liver tumor of
animals showing a greater efficacy of PAI compared to PEI
[1,4,19,20]; on the other hand, human studies only com-
pared local recurrence and survival rates without evaluat-
ing tumor necrosis whereas, to our knowledge, the only
study carried out on animals evaluated just the area of
coagulation after 30 minutes from the injection of ethanol
or acetic acid in the liver tumor [20].
An interesting previous study in healthy rats compared the
effect of the injection of 300 µl of pure ethanol and 100 µl
of 50% acetic acid separately into different sites of the
same liver. Acetic acid showed a more homogeneous dis-
tribution and better infiltrating ability than pure ethanol
[11].
Basing on this experiment, we evaluated in our study
safety, efficacy and percentage of necrosis produced in a
liver tumor with a single ultrasound-guided session of PEI
(300 µl 95%) in comparison to an equal single session of
PAI (100 µl 50%) in male rats with BW7756 hepatoma,
sacrificed 14 days after the procedure.
We chose to compare PAI and PEI at different dosages
since it is already known that, volume being equal, acetic
acid is able to induce an area of necrosis of hepatic tumors
three times greater than that caused by ethanol according
to some authors, and even ten times greater according to
others. In fact, a previous study showed that acetic acid
produced significantly larger zones of tumor coagulation
compared with ethanol when injected in equal volumes
into VX2 carcinoma in rabbits killed 30 minutes after the
procedure [20].
Conversely, information is lacking about the safety of
both treatments in rats with hepatoma sacrificed 14 days
after the procedure.
The choice of comparing PAI and PEI at different dosages
(100 µl for PAI and 300 µl for PEI) also depends on the
fact that acetic acid has a greater diffusion through
tumoral tissue than ethanol, and, therefore, a smaller
quantity is needed to kill tumor cells [20]. On the other
hand, increasing the dosage of acetic acid to values equiv-
alent to those of ethanol (300 µl) probably caused more
deaths among rats treated with PAI while decreasing the
dosage of the well-tolerated ethanol to values equivalent
to those for acetic acid (100 µl) might have been inade-
quate for PEI treatment. Studies on safety of these meth-
Representative histologic specimens of the liver after PEI [A]  and PAI [B] Figure 4
Representative histologic specimens of the liver after PEI [A] 
and PAI [B]. Perivascular (v) viable tumor cells (b) and necro-
sis with cellular debris (c).
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ods have shown that risk and complications rates of PAI
treatment are nearly superimposable to those of PEI [21-
23].
On the contrary, our results show no significant difference
between PEI and PAI as to the efficacy (percentage of
necrosis and histological changes), but significant differ-
ence as to safety (6% of deaths after PEI vs. 47% after PAI).
These data were confirmed by repeating the experiment
with PAI procedure in 13 rats and performing an autopsy
in the 5 rats died within 30 minutes after the procedure,
thus demonstrating that the high number of deaths (5/13
rats) was not due to technical failure but to acute compli-
cations.
However, this may not automatically apply to humans as
the majority of hepatocellular carcinomas in human sub-
jects occur in the setting of cirrhosis where the non-
tumoral tissue is firmer than the tumor structure and ace-
tic acid, as well as ethanol, cannot diffuse much in the sur-
rounding non-tumoral tissue. This could be the reason
why some human studies have concluded similar or even
better safety and efficacy when comparing PAI to PEI
[1,4,5,19]. A recent study in patients awaiting liver trans-
plantation showed that PEI induced complete necrosis of
HCC in 65% of cases, whereas in patients with HCC
undergoing PAI treatment, complete response was
obtained in 69% of cases [24,25]; however, doubt arises
about the real value of this complete response after PAI
treatment because of the lack of histological evidence.
Conclusion
In our study on animals, we did not observe complete
necrosis either with PEI or PAI treatment, because the sin-
gle treatment session we performed on each animal
would not be sufficient to cause it.
Interestingly, a single dose of treatment gave a percentage
of necrosis of nearly 50% for both percutaneous treat-
ments, with a mortality rate quite lower for PEI than PAI.
It is true that the same percentage of necrosis as PAI was
obtained with a three times higher dosage of PEI, but in
spite of this, PEI proved to be safer than PAI. Therefore,
our data principally show that the ability of a single treat-
ment session to cause tumor necrosis is nearly 50% both
for PAI and PEI. However, in choosing the best possible
chemical percutaneous treatment, both efficacy and
adverse reactions have to be taken into consideration.
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